Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43907125" target="_blank" >RIV/00216208:11120/12:43907125 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/12:43907125

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.ijantimicag.2012.07.018" target="_blank" >http://dx.doi.org/10.1016/j.ijantimicag.2012.07.018</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijantimicag.2012.07.018" target="_blank" >10.1016/j.ijantimicag.2012.07.018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis

Popis výsledku v původním jazyce

Post hoc analysis of a non-comparative, prospective, multicentre, phase IIIb study was performed to compare efficacy and safety of anidulafungin in elderly (>= 65 years) versus non-elderly (<65 years) Intensive Care Unit (ICU) patients with candidaemia/invasive candidiasis (C/IC). Adult ICU patients with confirmed C/IC meeting >= 1 of the following criteria were enrolled: post-abdominal surgery; solid tumour; renal/hepatic insufficiency; solid organ transplantation; neutropenia; age >= 65 years. Patients received anidulafungin (200 mg on Day 1, 100 mg/day thereafter) for >= 10 days followed by optional azole step-down therapy for a total treatment duration of 14-56 days. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Primary efficacy analysis was performed in the modified intent-to-treat (mITT) population (n = 170), excluding unknown and missing responses. In total, 80 patients (47.1%) were aged >= 65 years and 90 (52.9

Název v anglickém jazyce

Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis

Popis výsledku anglicky

Post hoc analysis of a non-comparative, prospective, multicentre, phase IIIb study was performed to compare efficacy and safety of anidulafungin in elderly (>= 65 years) versus non-elderly (<65 years) Intensive Care Unit (ICU) patients with candidaemia/invasive candidiasis (C/IC). Adult ICU patients with confirmed C/IC meeting >= 1 of the following criteria were enrolled: post-abdominal surgery; solid tumour; renal/hepatic insufficiency; solid organ transplantation; neutropenia; age >= 65 years. Patients received anidulafungin (200 mg on Day 1, 100 mg/day thereafter) for >= 10 days followed by optional azole step-down therapy for a total treatment duration of 14-56 days. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Primary efficacy analysis was performed in the modified intent-to-treat (mITT) population (n = 170), excluding unknown and missing responses. In total, 80 patients (47.1%) were aged >= 65 years and 90 (52.9

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EE - Mikrobiologie, virologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Antimicrobial Agents

ISSN

0924-8579

e-ISSN

—

Svazek periodika

40

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

521-526

Kód UT WoS článku

000311347000005

EID výsledku v databázi Scopus

—